Molecular Imaging in Breast Cancer Screening

A description of how molecular breast imaging is being used alongside other technologic advances in breast imaging for breast cancer screening.

Course ID: Q00541 Category:
Modalities: , , ,

2.5

Satisfaction Guarantee

$29.00

View cart

This course has been approved for 2.5 Category A credits.
No discipline-specific Targeted CE credit is currently offered by this course.

Outline

  1. Introduction
  2. Primary Screening
  3. Need for Supplemental Screening after DBT
  4. Supplemental Screening of High-Risk Women with Dense Breasts
  5. Supplemental Screening of Average-Risk Women with Dense Breasts
  6. Decision Algorithm for Supplemental Screening
  7. Screening Workflow and Patient Management
  8. Implementing MBI in Clinical Practice
  9. Case Studies
    1. Supplemental Screening for Dense/Complex Mammograms
      1. Case 1
      2. Case 2
      3. Case 3
      4. Case 4
    2. High-Risk Screening and MR Imaging Contraindications
      1. Case 5
      2. Case 6
    3. MBI Diagnostic Use for Problem Solving
      1. Case 7
      2. Case 8
      3. Case 9
    4. False Positives
      1. Case 10
      2. Case 11
      3. Case 12
  10. Conclusion

Objectives

Upon completion of this course, students will:

  1. know the authors’ primary imaging modality for breast cancer screening
  2. know a particular patient population for which detecting breast cancer can be a challenge for mammography
  3. know the expectations for routine supplemental breast cancer screening
  4. understand the decision to switch from 2D digital mammography to DBT as the primary imaging modality for women presenting for breast cancer screenings
  5. be familiar with the decision to continue with supplemental screening of women with dense breasts even after conversion to DBT for primary screening
  6. recognize the advantages of MR imaging with IV gadolinium as a supplemental screening method for high-risk women with dense breasts
  7. know why MR imaging with IV gadolinium is not suitable as a supplemental screening technique for all patients
  8. identify the patient populations for which MR imaging would be recommended as an effective screening tool
  9. be familiar with the guidelines supporting MR for adjunct breast cancer screening
  10. be aware of the reasons mentioned in the article why MBI might be offered as an alternative imaging solution to MR as a supplemental breast cancer screening method
  11. know the origins for the basis of MBI, due to incidental tracer uptake in breast tumors
  12. understand why the 99mTc-sestamibi radiotracer is not affected by anatomic characteristics such as density or surgical distortion
  13. be familiar with the limitations of camera detectors in early 99mTc-sestamibi breast imaging
  14. know how the sensitivity of gamma cameras has been enhanced in recent years
  15. be familiar with the relative radiation dose risk of MBI
  16. know the effects of adding MBI to digital mammography versus mammography alone
  17. understand how adding MBI as an adjunct breast screening technique compares to the addition of other adjunct screening techniques
  18. be familiar with the ACR’s BI-RADS classifications of breast density
  19. know the next screening step for women who have been objectively scored as having dense breasts on the BI-RADS scoring system
  20. know which patient populations would be recommended for either MR or MBI imaging as adjunct screening after mammography
  21. understand the type of density scoring provided by breast density assessment software, as compared to a radiologist’s interpretation
  22. know what should be reported to the referring physician in the final mammography report
  23. know this site’s screening recommendation to high-risk women with dense breasts
  24. be familiar with the roles of the scheduling personnel at this site once a patient has been recommended for MBI
  25. know the menstrual cycle phase when MBI is to be performed
  26. know when MBI imaging should commence after radiotracer injection
  27. be familiar with what should be considered for documentation in an MBI report
  28. know why biennial MBI supplemental screening is recommended in non-high-risk women
  29. know when positive findings at MBI should be evaluated with targeted ultrasound
  30. know the roles of the various personnel when implementing MBI in clinical practice
  31. be familiar with the various entities for which education was identified as being crucial to the maintenance and continuation of the clinical site’s MBI program
  32. know why the patient in Case 1 was recommended for supplemental screening with MBI
  33. know the aspect of MBI which reassures both radiologists and patients in cases where a mammogram is too dense for accurate interpretation and MBI is clearly negative
  34. know why the patient in Case 8 was recommended for MBI
  35. understand why the patient in Case 11 was recommended for supplemental screening